The Lancet Infectious Diseases
Издатель: Elsevier · ISSN 1473-3099 · 78 статей
- Can better oral care reduce non-ventilator hospital-acquired pneumonia?
- Mpox: virus expansion, evolution, and immune recognition
- South Sudan's first 100 days of Bundibugyo Ebola readiness
- Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1
- Cross-reactive Bundibugyo antibody responses in Guinean survivors of Ebola virus and recipients of rVSVΔG-ZEBOV-GP (Ervebo) in an outbreak setting
- US measles elimination status likely to be lost as cases surge
- Mortality and prognostic factors in invasive aspergillosis: a systematic review and individual patient data meta-analysis
- Merck's alimatravir licensing deal receives mixed response
- WHO updates guidelines for visceral leishmaniasis
- The Global Fund supports malaria response in DR Congo
- Infection prevention and control gaps in Pakistan
- Bruce Ribner
- Sneeze: The History and Science of the Common Cold, David Miles. August Books (2026), 352, £10·99, 13, ISBN: 978-1-804-36924-1
- The Silent Killer: The Untold Story of Humanity's Deadliest Infection and the Fight to Eradicate It, Liora Ashfield. independently published (2026), 104, £15·78, ISBN: 9798254726913
- Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
- Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
- Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
- Effect of a community-based behavioural intervention bundle to improve antibiotic use and patient management in Burkina Faso and DR Congo (CABU-EICO): a cluster-randomised controlled trial
- Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
- Improving the treatment of invasive fungal infections: novel antifungal and host-directed therapies
- Thelazia callipaeda: an emerging zoonotic eyeworm from Asia to Europe and North America
- Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
- Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
- Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons
- Expert consensus on case definitions in human loiasis: a Delphi study
- Therapeutic plasma exchange and continuous renal replacement therapy for severe dengue with multiorgan failure: a case report and focused review
- A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models
- Understanding and exploiting superspreading to disrupt Mycobacterium tuberculosis transmission
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime–zidebactam alongside phage therapy in the USA
- Lymphoma-like endoscopic appearance of lymphogranuloma venereum